Program
nisotirostide
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity, led by Eli Lilly.
Furthest: phase 2, since Mar 25, 20254 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 41 open or running | phase 2since Mar 25, 2025 | Nov 20, 2020 | May 2027phase 2 · NCT06897475 |
- Named in Eli Lilly’s own pipeline as
Nisotirostide
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04641312 · 67 enrolled · Germany
- May 16, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05377333 · 94 enrolled · United States
- Oct 13, 2022Phase 1 study in OverweightNCT05582096 · 38 enrolled · United States
- Mar 25, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06897475 · 200 planned · United States, Canada, Germany and more
Ahead
- May 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT06897475
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06897475Diabetes Mellitus, Type 2 · United States, Canada, Germany and more | 2 | Recruiting | May 2027 | 200 |
| NCT05582096Overweight · United States | 1 | Completed | Jun 8, 2023 | 38 |
| NCT05377333Diabetes Mellitus, Type 2 · United States | 1 | Completed | Nov 22, 2023 | 94 |
| NCT04641312Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Dec 21, 2021 | 67 |
How it is read
Names in the registry
- “LY3457263”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.